Avita Medical Ltd ( (RCEL) ) has released its Q3 earnings. Here is a breakdown of the information Avita Medical Ltd presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AVITA Medical Ltd is a therapeutic acute wound care company specializing in innovative solutions for wound healing, primarily operating in the healthcare sector with a focus on the RECELL System for burn and trauma wounds.
In its third-quarter 2025 financial results, AVITA Medical reported a commercial revenue of $17.1 million, marking a 13% decrease compared to the same period in 2024, alongside a reduction in operating expenses by 24% to $23.0 million. The company also improved its net cash usage, highlighting a focus on financial efficiency.
Key financial metrics include a net loss improvement to $13.2 million from $16.2 million in the previous year, with a gross profit margin of 81.3%. The company achieved significant milestones such as CE Mark approval for RECELL GO® in Europe and restored reimbursement clarity in the U.S., which are expected to bolster future revenue streams.
Despite the lowered full-year revenue outlook to $70-$74 million from the previous $76-$81 million guidance, AVITA Medical remains optimistic about its strategic focus on high-value U.S. burn and trauma centers and its potential for growth in the $1.3 billion addressable market.
Looking forward, AVITA Medical aims to enhance its financial flexibility and continue its disciplined growth strategy, with plans to provide updates on capital and growth strategies in early 2026, while maintaining a strong emphasis on cash management and commercial execution.